Email address
[email protected]Contact number
+1 212 295 6834Share profile
Up and Coming
Provided by Christopher Barnstable-Brown
Chris Barnstable-Brown's nationally recognized practice focuses on mergers and acquisitions, corporate governance and financing transactions, with particular emphasis on the technology and life sciences industries. Client sources in Chambers USA (Corporate/M&A) said, “Chris gives practical, actionable advice. He has a great disposition and is a great business person,” adding “he has excellent awareness of client priorities and is very effective at negotiating constructively to find solutions to difficult issues,” and “it’s a pleasure to work with him.”
Chris advises a diverse array of clients, including public and private companies, venture capital funds and private equity sponsors, and financial institutions. He regularly advises on bet-the-company M&A and strategic transactions across industries, as well as a range of corporate governance, financing, public company and emerging company matters. Chris has particular expertise working with technology, life sciences, fintech and AI-focused companies, investors and sponsors.
Chris has been repeatedly recognized as a leading lawyer for Corporate/M&A by, among others, Chambers USA (New York), The Legal 500, The M&A Advisor and New York Super Lawyers. Chris is a frequent speaker and author on corporate and M&A matters, and he has been featured in The Wall Street Journal, Bloomberg Law and Law360. Chris has recently led transactions for Medtronic, Google Ventures, Blue Apron, RA Capital, Telix Pharmaceuticals, Climb Bio, Solid Biosciences, Thermo Fisher Scientific, Revvity (f/k/a PerkinElmer), CARISMA Therapeutics, Marley Spoon, Bluestone Equity Partners, IVERIC Bio, Leerink Partners and Goldman Sachs.
Before joining WilmerHale, Chris was a corporate associate at Cravath, Swaine & Moore LLP and a judicial law clerk for the Honorable Boyce F. Martin, Jr. of the US Court of Appeals for the Sixth Circuit. Chris was born in Louisville, Kentucky.
Chris has recently led transactions for Medtronic, Google Ventures, Blue Apron, RA Capital, Telix Pharmaceuticals, Climb Bio, Solid Biosciences, Thermo Fisher Scientific, Revvity (f/k/a PerkinElmer), CARISMA Therapeutics, Marley Spoon, Bluestone Equity Partners, IVERIC Bio, Leerink Partners and Goldman Sachs.
- Medtronic plc on numerous M&A and strategic transactions, including its acquisitions of Avenu Medical and Visionsense, its strategic transaction with Cosmo Pharmaceuticals to pursue artificial intelligence driven medtech devices, and $337 million product funding arrangements with Blackstone
- Blue Apron in numerous transactions, including its “asset-light” asset sale transaction with FreshRealm and subsequent sale to Wonder Group, founded by Marc Lore
- Various investment funds on numerous transactions, including: Google Ventures’ investments in various private companies; RA Capital in PIPE investments in Vor Biopharma, Inhibrx, and UroGen and a security purchase agreement with SAB BIO; and Bluestone Equity’s investments in Qloo and Rhombus
- Telix Pharmaceuticals in its acquisition of QSAM Biosciences
- Revvity (f/k/a PerkinElmer) in its acquisition of Oxford Immunotec for $591 million
- Climb Bio in its acquisition of Tenet Medicines, and concurrent PIPE financing
- Durata Therapeutics in its sale to Allergan for $675 million plus CVRs of up to $155 million
- Amplitude Healthcare Acquisition Corporation in its $550 million deSPAC business combination with Jasper Therapeutics
- Solid Biosciences in its acquisition of AavantiBio, and concurrent PIPE financing
- PTC Therapeutics in its acquisition of Agilis Biotherapeutics
- CARISMA Therapeutics in its merger with Sesen Bio, and concurrent PIPE financing
- WeWork in numerous acquisition and sale transactions, including in respect of Teem Technologies, Prolific Interactive, SpaceIQ and Conductor
- Private equity firm Lindsay Goldberg in its acquisition of the Applied Technology Division of Computer Sciences Corporation
- Archer Daniels Midland Company in its agreement to acquire GrainCorp Ltd. of Australia for $3.5 billion
- ZebiAI Therapeutics in its acquisition by Relay Therapeutics
- Leerink Partners as financial advisor in connection with the merger between ARS Pharmaceuticals and Silverback Therapeutics
- Acquco in its $160 million Series A financing
- XLMedia plc in its acquisition of the CBWG sports media, gaming and betting business
- Tetraphase Pharmaceuticals in its merger with AcelRx Pharmaceuticals and its later agreement to be acquired by Melinta Therapeutics
Provided by Chambers
Christopher Barnstable-Brown is noted for his experience advising on mergers, acquisitions and financings. He is particularly sought after by life sciences and tech industry clients, among others.
Provided by Chambers
It's a pleasure to work with him. He understands the business considerations that really drive a transaction and he's always sure to accommodate them.
He knows our business and understands what we are trying to accomplish. Chris puts himself in our shoes and helps us to achieve our objectives.
Chris gives practical, actionable advice. He has a great disposition and is a great business person.
He has excellent awareness of client priorities and is very effective at negotiating constructively to find solutions to difficult issues.
It's a pleasure to work with him. He understands the business considerations that really drive a transaction and he's always sure to accommodate them.
He knows our business and understands what we are trying to accomplish. Chris puts himself in our shoes and helps us to achieve our objectives.
Chris gives practical, actionable advice. He has a great disposition and is a great business person.
He has excellent awareness of client priorities and is very effective at negotiating constructively to find solutions to difficult issues.